Counsyl specializes in genetic testing technologies that provide critical insights into hereditary cancer risks, prenatal care, and mental health management. Their MyRisk® test evaluates 48 genes to assess the risk of developing 11 types of hereditary cancers, including breast and ovarian cancer. This test, which requires only a blood or saliva sample, can deliver results within two weeks and is designed to help patients and healthcare providers make informed decisions regarding cancer prevention and treatment options. Additionally, Counsyl offers tests like Foresight® and Prequel® that assist expectant parents in understanding fetal health and sex, as well as identifying potential genetic conditions early in pregnancy.

The company also emphasizes the importance of personalized healthcare through its genetic insights, which can guide treatment plans and medication management based on individual genetic profiles. Their resources include patient guides and provider portals that facilitate access to testing and results, ensuring that both patients and healthcare providers have the necessary tools to navigate genetic health concerns effectively. By integrating genetic testing into routine healthcare, Counsyl aims to empower individuals with knowledge that can significantly impact their health and well-being across various life stages.

United States

Counsyl

Company Details